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Recent reports regarding the re-emergence of parasite sensitivity to chloroquine call for a new 
consideration of this drug as an interesting complementary tool in malaria elimination efforts, given 
its good safety profile and long half-life. A randomized (2:1), single-blind, placebo-controlled trial was 
conducted in Manhiça, Mozambique, to assess the in-vivo efficacy of chloroquine to clear plasmodium 
falciparum (Pf) asymptomatic infections. Primary study endpoint was the rate of adequate and 
parasitological response (ACPR) to therapy on day 28 (PCR-corrected). Day 0 isolates were analyzed 
to assess the presence of the PfCRT-76T CQ resistance marker. A total of 52 and 27 male adults were 
included in the CQ and Placebo group respectively. PCR-corrected ACPR was significantly higher in 
the CQ arm 89.4% (95%CI 80–98%) compared to the placebo (p < 0.001). CQ cleared 49/50 infections 
within the first 72 h while placebo cleared 12/26 (LRT p < 0.001). The PfCRT-76T mutation was present 
only in one out of 108 (0.9%) samples at baseline, well below the 84% prevalence found in 1999 in 
the same area. This study presents preliminary evidence of a return of chloroquine sensitivity in 
Mozambican Pf isolates, and calls for its further evaluation in community-based malaria elimination 
efforts, in combination with other effective anti-malarials. Trial registration: www.clinicalTrials.gov 
NCT02698748.
In recent years, interest in the potential use of Chloroquine (CQ) has re-emerged, partly on account of the obser-
vation that the prevalence of molecular markers associated with CQ resistance among circulating parasites has 
decreased after discontinuing the use of the drug. The emergence of CQ resistance was first documented in 
Southeast Asia and South America less than a decade after its introduction as first-line treatment and spread to 
the East of Africa and the rest of the continent by the end of the 1970’s1–3. In 2001 the World Health Organization 
(WHO) recommended artemisinin-based combination therapy (ACT) as the first line treatment for uncompli-
cated malaria in countries where Plasmodium falciparum (Pf) malaria had become resistant to CQ4, and since 
then the use of CQ for the treatment of Pf has progressively been abandoned.
Drug-resistant microorganisms are generally thought to suffer from a fitness cost associated with their 
drug-resistant trait5, inflicting them a disadvantage when the drug pressure reduces. Such finding implies that 
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resistance might be reversible if drug use is discontinued. A point mutation in the 76th position of the P. fal-
ciparum CQ-resistance transporter gene (PfCRT) from a lysine in sensitive parasites (K76) to a threonine in 
resistant parasites (76 T) has been associated with CQ-resistant falciparum malaria6. Analysis of the population 
frequencies of the mutations in PfCRT known to be associated with CQ resistance7 and assessment of in vitro 
activity of the drug8, 9 in Malawian parasite isolates have indicated that CQ resistance may revert to sensitivity 
within a decade of withdrawal of the drug10. Similar drops, have been shown in Zambia11, Tanzania12 or coastal 
Kenya (Kilifi)13, years after CQ had been withdrawn. Translation of in vitro sensitivity to in vivo efficacy has also 
since then been demonstrated in Malawi14, where CQ efficacy in patients has been confirmed as very high14, and 
its use as monotherapy in a clinical trial context -albeit not a WHO recommendation- has also been shown to be 
similarly efficacious to its combination with other partner drugs15.
In Mozambique, which borders in the west with Malawi, the national policy moved away from using CQ in 
2003–4. A study conducted among children from Manhiça District in 1999 revealed a PfCRT 76 T prevalence of 
84%16. However, a recent study performed in Gaza Province showed also an important decline of PfCRT K76T 
prevalence from more than 90% in 2006 to around 30% in 201017. A similar study conducted in a different part 
of the country also confirmed this tendency towards an increase of wild type parasites and thus CQ sensitivity18. 
The last available efficacy results for CQ derived from an in vivo study performed in Mozambique in the year 2001 
showed that the day 28 efficacy was 47.1%19.
Altogether, these data suggest that, in the absence of drug pressure, CQ may be regaining sensitivity against 
P. falciparum in certain malaria-endemic settings of Sub-Saharan Africa. While this does not support the rein-
troduction of CQ as first line therapy in such settings at this point, it does suggest that, if proven sensitive in a 
given area, CQ could be considered as a complementary tool to interrupt transmission in the context of malaria 
elimination efforts.
With this rationale in mind, we conducted a randomized placebo-controlled single blinded clinical trial to 
assess the efficacy of CQ (vs. placebo) to treat asymptomatic infections among healthy adult Mozambican volun-
teers. We complementarily present prevalence estimates of the PfCRT K76T molecular marker of CQ resistance 
among parasites among the study population in 2015.
Methods
The protocol for this trial and supporting CONSORT checklist, are available and annexed as supporting 
information.
Study design. Between January and June 2015, a randomized, single-blinded, placebo-controlled trial was 
conducted in the district of Manhiça, southern Mozambique, to treat asymptomatic infections among healthy 
adults from the community. This study population was considered as the most ethical option for the first in-vivo 
study to take place since 2001, when CQ had been shown to be poorly efficaciuos. A placebo comparator was 
consequently used to accurately account for the effect that the high levels of immunity expected in the study 
population would have on natural parasite clearance of low parasitaemic infections20.
Study site. The district of Manhiça counts with a demographic surveillance system (DSS) set up in 1998 
by the Centro de Investigação em Saúde de Manhiça (CISM), which currently provides accurate demographic 
information on its circa 178,000 inhabitants. The region has two distinct seasons – a warm and rainy season 
from November to April, and a cooler and drier season the rest of the year. Malaria transmission is perennial 
but shows marked seasonality, with Plasmodium falciparum (Pf) being the predominant species, and Anopheles 
funestus the main vector. Study participants were selected from areas within Manhiça were clinical malaria in 
children was historical known to be high (above 40%) and asymptomatic infections in adults were expected in 
the community21.
Screening and recruitment of study subjects. The study population comprised adult males with 
microscopically confirmed, asymptomatic malaria infections. In order to find these subjects, a random list was 
generated from the DSS databases, and individuals were visited in their household, and screened for malaria 
through finger-prick with an HRP2-based rapid diagnostic test (RDT) and a blood slide. Blood slides were only 
read at CISM’s laboratory in those cases found to be positive by the RDT (“pre-screened positive”), providing a 
final confirmation of malaria infection and density of parasitaemia. On the following day, such individuals were 
again visited at home, and only if they remained symptomless were offered to be included in the study. Study 
staff enquired about the presence of symptoms by asking a series of questions following a standardised clinical 
questionnaire. Asymptomatic malaria was defined as the absence of any proactively referred symptom of disease 
as referred by the individual, together with a documented axillary temperature <37.5 °C. Symptomatic patients, 
irrespective of being infected or not, were assessed by the study clinician and referred to the health system if 
needed. Females were not screened on account of the Mozambican Ethics Committee’s recommendation to avoid 
exposing to placebo malaria-infected women of child-bearing age which may be pregnant and thus prone to 
developing severe disease. Other inclusion criteria included Pf malaria infection with an asexual blood density 
≥100 p/µL but <10,000 p/µL. Key exclusion criteria included presence of any other co-existing clinical condition 
or symptom that in the opinion of the recruiting physician would not allow the individual to be considered a 
“healthy” asymptomatic carrier; axillary temperature > = 37.5 °C; intake of any medication which may interfere 
with antimalarial efficacy or antimalarial pharmacokinetics, such as cotrimoxazole; history of hypersensitivity 
reactions or contraindications to CQ; and known HIV concomitant infection under antiretroviral treatment. 
Individuals aged 18 years or more satisfying the inclusion criteria were enrolled if they signed a detailed written 
informed consent. Individuals aged 16 were offered participation provided their legal guardians also assented for 
participation.
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Treatment. After the pre-screening visit (Day “−1”), a screening evaluation was conducted 24 hours later 
(day 0) to check all inclusion and exclusion criteria, with a particular emphasis on ensuring that symptoms had 
not appeared. Eligible patients were randomly assigned to receive CQ (Arm 1) or Placebo (PL; arm 2), according 
to a 2:1 (CQ:PL) scheme, so as to have more patients in the CQ arm to provide better estimates for its cure rates. 
Patients having received on day 0 a study drug, but confirmed by the blood slide to be malaria infection negative 
or <100 parasites/µL were considered protocol violations, and excluded from the analysis. A randomization list 
was generated using the online available randomizer software (http://www.randomizer.org/). Study staff carried 
the study medication and directly supervised the three-day long treatment. Chloroquine sulphate (Meriquine®; 
250 mg; 150 mg of chloroquine base; Baroda, India) was administered at a total dose of 25 mg/kg (expressed as 
mg of CQ base per kg body weight, once daily during 3 consecutive days, following the schedule 10 mg/kg Day 1; 
10 mg/kg day 2 and 5 mg/kg day 3; or four, four and two pills per day, respectively). A similarly-looking placebo 
not containing any active principle, and prepared at the department of pharmacology of the Hospital Clinic, 
Barcelona, Spain, was administered to those allocated this intervention following an identical scheme. All treat-
ments were directly observed for a minimum of 30 min. Any subject vomiting during this observation period was 
re-treated with the same dose of either CQ or placebo, and observed for an additional 30 min. Repeated vomiting 
implied withdrawal from the study and the use of rescue treatment. Treatment of symptomatic malaria infections 
or rescue therapy in cases of early or late treatment failure followed national Mozambican guidelines and included 
the use of artemether-lumefantrine (AL)22.
Evaluation. Follow-up visits were planned on days 1, 2, 3, 7, 14, 21 and 28 after enrolment, or at any time 
point should the enrolled individual develop any symptoms of sickness. Individuals who discontinued either 
study drug were excluded from the study. Vital signs and body temperature were assessed during each follow-up 
visit. Adverse events were recorded and assessed for severity and association with study medication.
Thick and thin Giemsa-stained blood slides were prepared prior to the administration of the drug and at every 
follow-up visit. Slides were examined by two independent microscopists and considered negative if no parasites 
were seen after examination of 200 oil-immersion fields in a thick blood film. Parasite density was estimated 
using the Lambaréné method23 which counts parasites against an assumed known blood volume. Density of 
P. falciparum was assessed from blood-spots collected in filter paper through real-time quantitative polymer-
ase chain-reaction (qPCR) assay targeting 18S ribosomal RNA (rRNA)24, 25. Blood spots for PCR analysis were 
collected using 3M Whatman™ filter papers at baseline and at days 7, 14, 21 and 28, on the day of treatment 
failure or at any other unscheduled visit, and subsequently stored at 4 °C in plastic zip bags containing silica gel 
dessicant. PCR was performed centrally (Barcelona, Spain) for all cases of recurrent parasitaemia from day 7 
onwards, or for whom evidence of parasite clearance had been documented, and including DNA extraction using 
a QIAamp DNA Mini Kit (Qiagen). The three polymorphic genetic markers MSP1, MSP2, and GluRP, were also 
investigated to distinguish recrudescence from new infections, according to WHO recommended procedures26. 
Recrudescence was defined as at least one identical allele for each of the three markers in the pre-treatment and 
post-treatment samples. New infections were diagnosed when all alleles for at least one of the markers differed 
between the two samples.
Clinical trial outcomes. Treatment outcomes were classified on the basis of an assessment of the parasi-
tological and clinical response to antimalarial treatment according to the latest WHO guidelines27. However, 
as all recruited subjects were asymptomatic at baseline, some of the standard clinical endpoints such as fever 
clearance time were not applicable. The primary efficacy outcomes were the PCR-corrected early treatment fail-
ure (ETF), late clinical failure (LCF), late parasitological failure (LPF) and adequate clinical and parasitological 
response (ACPR) at day 28. ACPR was defined as the absence of parasitemia at the end of the trial’s follow-up 
period (Day 28), regardless of axillary temperature, without having previously met any of the criteria for early and 
late treatment failure. In the PCR-adjusted analyses, patients with recurrent infection were considered ACPR if 
this was classified as a new infection. Secondary outcomes included 28 day-uncorrected ACPR (crude efficacy), 
time to parasite clearance, parasite clearance curve during the first 72 hours of follow-up, and prevalence of 
chloroquine-resistance conferring PfCRT K76T mutation in pre-treatment infections.
Assessment of PfCRT K76T mutations. Purified DNA templates were amplified using 2720 Thermal 
Cycler (Applied Biosystems) by nested PCR amplification followed by Sanger sequencing for PfCRT gene. In brief, 
a first round of amplifications was performed in 25 μl reactions including 5 μl of template DNA, 0.5 μM of each 
forward (PfCRT_F-5′tttaggtggaggttcttgtctt-3′) and reverse (PfCRT_R-5′ atacttaattgaagaacaaatgattgga-3′) primers 
and 1x HOT FirePol Master Mix (Solis BioDyne; Cat. No. 04-27-00125). The template DNA was denatured at 
95 °C for 15 min in a thermocycler, followed by 25 cycles of amplification (95 °C for 1 min, 52 °C for 45 sec, and 
72 °C for 45 sec) and a final extension at 72 °C for 10 min. A reaction using 5 μl of PCR-grade water instead of tem-
plate DNA was included as a negative control. For the nested amplification, 5 μl of the PCR product from the first 
amplification was used as the template in a PCR reaction (50 μl final volume) containing 0.5 μM of each forward 
(PfCRT_F) and reverse (PfCRT_N_R-5′ttggtaggtggaatagattctct-3′) primers and 1x HOT FirePol Master Mix (Solis 
BioDyne). The reaction volume was make up by PCR-grade water. The template DNA was denatured at 95 °C for 
15 min in a thermocycler, followed by 35 cycles of amplification (95 °C for 30 sec, 50 °C for 45 sec, and 72 °C for 45 
sec) and a final extension at 72 °C for 10 min. PCR products were run on 2% agarose (Invitrogen) gels in 1 × TBE 
buffer (Thermo Fisher Scientific) to determine the presence and size of the amplified DNA. PCR products were 
visualized using a UV trans-illuminator. Both PCR primer sets were also tested with human gDNA to check their 
specificity. Three positive (7G8, Dd2, and V1/S) controls with known PfCRT_76 T allele were also processed and 
amplified at the same time as the studied samples. Positive and negative controls were added in every run. The 
expected size of the nested PCR was 319bp covering amino acid positions 35 to 120 from PfCRT in the 3D7 strain. 
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PCR products were quantified using EPOCH Biotech system. Approximately 1200ng of PCR products were sent 
to Genewiz, following safety instructions for the accurate shipment of PCR amplicons. PCR sequencing was per-
formed in both directions using specific forward and reverse primers of studied genes. The variations in the test 
sequences were identified by sequence alignment against reference sequence of 3D7 (PF3D7_0709000) retrieved 
from PlasmoDB.
Data management and statistical analysis. Data were recorded using standardized questionnaires spe-
cifically designed for this study, which were doubled-entered into a study-specific database created using open 
clinica software (OpenClinica Enterprise - Electronic Data Capture Software for Clinical Trials version 3.1.2, 
OpenClinica LLC, Waltham, MA, USA). Statistical analyses were performed with Stata 14 (Stata Corp, College 
Station, TX, USA), and the statistical significance level was set at 5%.
Safety outcomes were assessed in the intent-to-treat (ITT) population, which comprised all patients who 
received one or more doses of study medication and underwent at least one post-baseline safety assessment. 
Efficacy was calculated in the according-to-protocol population (ATP), which included all patients fulfilling 
the protocol eligibility criteria, who completed the three-day course of study medication, with no protocol vio-
lations, accomplishing the day-28 assessment and having an evaluable PCR in case of recurrent parasitaemia. 
Kaplan-Meier estimates were computed to estimate the cumulative proportion of treatment success until day 28; 
and Log-Rank tests used to compare the number of events in each arm. For such an analysis, losses to follow-up 
and study withdrawals were censored on the last day of follow-up. Cases with re-infections were also censored 
from the analysis on the day of detection. Finally, linear regressions and Likelihood Ratio Tests (LRT) of the 
log-transformed parasite densities during the first 72 hours of treatment were estimated to better characterize the 
parasite clearance curve during treatment between study groups.
Frequencies of mutations at PfCRT-76 alleles were calculated as the proportion of samples carrying the mutant 
form out of all samples processed. Samples carrying both wildtype and mutant forms, in which relative frequen-
cies could not be determined, were excluded from the denominator and numerator13.
Sample size calculations. Following WHO guidelines28, and assuming an unknown failure rate, a min-
imum sample of 50 patients was considered necessary to provide a meaningful evaluation of in vivo efficacy, 
regardless of the underlying rates of failure. For the placebo group, the proportion of parasites that are eliminated 
naturally by the host’s immune system after 28 days in Manhiça is unknown, but expected to be less than one per-
cent29–31. Thus, the sample size for the control group needed not be the same size as the treatment group in order 
to detect a significant difference in prevalence. If 25 controls were recruited (placebo arm), then, even if half of the 
controls were to clear their infections, we will still achieve a p-value of less than 0.001 from a Chi-square test with 
one degree of freedom (Fisher’s exact test would also yield a p-value less than 0.001). Therefore, our objective was 
to recruit 75 participants total, i.e. 50 to receive CQ and 25 to receive PL.
Ethical considerations. This protocol, consent forms and questionnaires were approved by the CISM local 
ethics committee, the Ethics Committee of the Hospital Clínic of Barcelona (HCB/2015/0122), the National 
Bioethics Committee of Mozambique (CNBS; Ref:173/CNBS/13) and the Mozambican pharmaceutical depart-
ment (Ref./N°4110/380/DF2014) before their implementation. The methodology used in this study was per-
formed in accordance with the relevant regulations and guidelines from all committees. All participants signed an 
Informed consent form prior to the initiation of any study related activities. All samples for the separate analysis 
of trends in CQ resistance were obtained under an informed consent, and after individual ethical approvals for 
each of the parent studies by CNBS. The trial was registered on January the 13th, 2015, at www.ClinicalTrials.gov 
(NCT02698748).
Results
Trial profile and baseline characteristics. A total of 1925 adult males were approached and pre-screened 
(Day −1) for symptomatology and malaria infection. Of those, 112 (5.8%) fulfilled a priori inclusion criteria and 
were randomized (Day 0) to receive either CQ (n = 73; 65.2%) or PL (n = 39; 34.8%). Median age of randomized 
individuals was 21.5 years (IQR 17–35). No significant differences were observed between subjects randomized to 
receive either CQ or PL (Table 1). Main reasons for exclusion was the absence of malaria parasites at pre-screen-
ing and/or the concomitant use of antiretroviral or antimalarial drugs. The ITT and ATP populations included 
112 and 79 individuals, respectively. One patient that should have received CQ was given by mistake PL, and con-
versely, two patients that should have received PL were treated with CQ, which resulted in 74 participants in the 
CQ arm and 38 in the PL. In those three cases, subjects continued with the same treatment for the entire 3 days. 
Two patients in the CQ group did not complete the entire 3-day long treatment. A single patient in the PL group 
had to be withdrawn from the study and given rescue treatment after developing clinical symptoms. 52 patients 
finalized the CQ treatment, and 27 finalized the PL. Of these, 47 subjects allocated to receive CQ (64%) and 22 to 
PL (56%) concluded with all available information the 28 day long follow-up (Fig. 1).
Safety. In terms of tolerability and safety of the interventions, the symptoms reported during the three-day 
treatment course did not significantly vary between study arms (Table 1). No serious adverse events occurred, and 
all AEs were very mild and deemed not related with the interventions except for a case of mild pruritus reported 
from one patient in the CQ group.
Efficacy. The day-28 PCR-uncorrected cure rate (i.e., the proportion of patients with ACPR, ATP population, 
without correcting by PCR) was 89.4% (42/47; 95% CI 80.5–98.2) for CQ, and 18.1% (4/22; 95% CI 2.1–34.3) 
for PL (p < 0.001). PCR-correction did not change the D28 ACPR for CQ, which remained 89.4% (42/47; 95% 
CI 80.5–98.2) given that the only new infection identified in this group was lost to follow-up after day 21; but 
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increased that of PL (28.6%; 4/14; 95% CI 4.9–52.2), as 8 of the treatment failures proved to be new infections, and 
were consequently excluded from the analysis (Table 2). Figure 2 illustrates the Kaplan Meier curves showing the 
treatment success cumulative proportion for each treatment until day 28, both for the PCR uncorrected (2a) and 
PCR-corrected (2b) in the ATP population.
Parasite clearance within first 72 hours. Only one (2%) of the 50 participants in the CQ arm still pre-
sented an infection (24 p/μL) 72 hours after the administration of the first dose. Conversely, 14 (54%) of the 26 
individuals in the placebo group were infected at the same point in time, with parasite densities ranging from 22 
to 28,089 p/μL. Finally, the linear regressions fitted to the log-transformed parasite densities at 0, 24, 48 and 72 
hours revealed significantly different rates of parasite clearance (LRT of interaction p-value = 0.02) between study 
arms (Fig. 3).
Variable
Treatment Group
p-value3Placebo CQ Total
Total Number of 
Participants on 
Day 0
38 74 112
Age (years)1 26 (14) [38]
29 (16) 
[64]
28 (15) 
[102] 0.222
Body 
Temperature (°C)1
36.5 (0.4) 
[38]
36.5 (0.3) 
[70]
36.5 (0.3) 
[108] 0.732
Weight (kg)1 55.3 (10.6) [37]
58.6 (8.8) 
[71]
57.5 (9.5) 
[108] 0.088
Parasite density 
(p/μL)2
488.3 
(864.9) 
[34]
534.0 
(1010.2) 
[62]
517.3 
(952.5) 
[96]
0.821
PCR Parasitemia 
(p/μL)2
185.5 
(349.9) 
[37]
169.4 
(332.0) 
[71]
174.8 
(336.7) 
[108]
0.818
Table 1. Baseline characteristics of participants at enrolment. 1: Arithmetic Mean (SD) [n] 2: Geometric Mean 
(SD) [n]. 3: T-test.
Figure 1. Consort flow diagram of study participants.
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Variable
Placebo CQ
p valueN = 27 N = 52
ACPRa (uncorrected) n 4 42 <0.001*
ETFb n 11 0 <0.001*
LCFc n 0 0 NA
LPFd n 9 7 0.037**
New infections (with 
PCR) n 8 1 0.034
Recrudescences (with 
PCR) n 1 1
No treatment outcome: loss 
to follow-up or missing or 
inconclusive PCR results
9 12 NA
ATPe day-28 efficacy (PCR-
uncorrected) n/N (95%CI) 
by optic microscopy
4/22 
(18.2%) 
[2.1–34.3]
42/47 
(89.4%) 
[80.5–98.2]
<0.001*
ATP day-28 efficacy (PCR-
corrected) n/N (95%CI)
4/14 (28.6) 
[4.9–52.2]
42/47 
(89.4%) 
[80.5–98.2]
<0.001*
Table 2. Treatment outcomes on day 28, according to treatment received (Placebo or chloroquine). 
aACPR:adequate clinical and parasitological response; bETF: early treatment failure; cLCF: late clinical failure; 
dLPF: late parasitological failure; eATP: According to protocol; NA: not applicable. *Fisher’s exact test; **Chi-
squared test.
Figure 2. PCR uncorrected (2A) and PCR-corrected (2B) Kaplan Meier curves showing the treatment success 
cumulative proportion for each study arm until day 28 in the ATP population. Cumulative risks of failure were 
computed for day 28 and Log-Rank tests used to compare the number of events that occurred in each arm. 
PCR-corrected curves censored participants who experienced a reinfection on the day it was detected.
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PfCRT 76 mutations among isolates from the clinical trial. Among 110 samples, 108 samples were 
used to assess the presence of PfCRT K76T mutation by bi-directional DNA sequencing. Further, these sequences 
were aligned, using NCBI-Blast online tool against the reference sequence of 3D7 (PF3D7_0709000) retrieved 
from PlasmoDB. Three positive control data were in accordance with existing data. Only one of the 108 (0.9%) 
samples analyzed was found to have the mutant allele (Fig. 4). Four additional samples (3.7%) had mixed infec-
tion, and wild type allele frequency was 95.4% (103/108).
Discussion
In the continuum of strategies governing the transition towards malaria elimination32, there has been renewed 
interest in the innovative reappraisal of CQ as an antimalarial to be used in community-based campaigns. 
However, evidence is needed to demonstrate that CQ-based regimens will be effective over a wide geographic 
area where malaria elimination interventions will be implemented. This study presents a return of chloroquine 
sensitivity in Mozambique approximately 12 years after its use was interrupted. In the last decade, the presence 
of resistant parasites has dropped from 84% in 199916 to 0.9% in 2015. Additionally, in 2015 chloroquine success-
fully cleared 89% of asymptomatic infections among a population of male adults from an endemic area, when 
compared to infections treated with placebo. The rate of parasite clearance was also significantly faster among 
chloroquine-treated infections compared to those left untreated and, as expected, there were no adverse events 
associated to the medications. This study provides the first evidence to support the idea that CQ could play a role, 
on its own or in combination with other drugs or tools, in the fight against malaria in Mozambique.
The drug efficacy observed in the present clinical trial is promising despite falling below the WHO recom-
mended 95% efficacy rate for antimalarial drugs28. The methodology used to assess efficacy in this study was 
unusual for an anti-malaria efficacy study, thus conditioning the interpretation of its results to the advantages and 
disadvantages of the clinical trial procedures followed. Comparing chloroquine versus placebo allowed to test 
the hypothesis that chloroquine was as inefficacious as not providing any treatment at all. By having an untreated 
Figure 3. Linear regressions fitted to the log-transformed parasite densities during the first 72 hours after first-
dose administration.
Figure 4. Prevalence of PfCRT K76 mutated, wildtype and mixed parasites from samples collected in 1999 
and 2015. Samples were genotyped using restriction fragment length polymorphism in 1999 and bi-directional 
DNA sequencing in 2015.
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control, this methodology allowed assessing whether the cleared infections observed in the chloroquine group 
were solely due to the body’s natural capacity to eliminate the parasite reservoir rather than due to the effect of the 
drug. The placebo group of this study revealed that approximately 18% of the low-parasitemia infections are nat-
urally cleared 28 days after they have been identified, a larger proportion compared to what has previously been 
reported23–25. In addition, only one individual developed clinical symptoms among all untreated asymptomatic 
participants. This is therefore an unprecedented opportunity for further exploration of the relatively unknown 
symptom-less malaria infection33, which will be performed in detail and presented in a separate article.
Considering the low in vivo efficacy of chloroquine detected in the same study area prior to this clinical trial19, 
the study only included asymptomatic infections to avoid treatment failures that could trigger complications to 
the study participants. This study population implies several limitations inherent to the nature of asymptomatic 
infections. First, the high levels of existing immunity in the study population may have augmented the efficacy 
of the drug, although this was controlled for in the analysis by observing the natural parasite clearance rate in 
the placebo group with the same levels of immunity20. Unfortunately, the study design did not consider regu-
lar estimations of parasite densities during the first days of follow-up, which limited our capacity to accurately 
estimate parasite reduction rates (PRR) in both treatment groups as a surrogate of drug efficacy34. Second, low 
parasitaemic infections (approximately 500 p/μL) could have potentiated drug efficacy, which needs to be assessed 
further in future studies involving clinical malaria cases with higher loads of parasite biomass. The evaluation 
of drug efficacy in low parasite density infections carried additional challenges, particularly when performing 
molecular analysis to comply with WHO standard analysis procedures35. Due to low parasitaemia, the sensitivity 
of the genotyping techniques was low, and therefore PCR-Corrected analysis was considered biased. As a result, 
PCR-uncorrected analysis should be considered as a more precise way of analyzing the efficacy of chloroquine in 
this particular study population. The standard PCR-Corrected analysis was also limited by the very nature of the 
control group, which consisted of natural, untreated, asymptomatic infections. Participants in the placebo group 
were consequently vulnerable to reinfections and parasite density oscillations around the microscopy detection 
threshold that could be interpreted as recrudescences or reinfections rather than as a chronic low parasitemic 
infection4.
Despite all of the above, the high in vivo efficacy found in Southern Mozambique through this clinical trial 
aligns well with the findings obtained molecularly that detected a sharp decline in the prevalence of drug-resistant 
parasites between 1999 (84%) and 2015 (0.9%) in the same area. Such a shift in the parasite population after the 
interruption of CQ use has been observed in several countries in Africa10, 12, 13, 36. This reversal to the wild type 
form of the PfCRT gene indicates that parasites carrying the mutant PfCRT may have a substantial fitness cost in 
the absence of CQ, thus leading to their decline in frequency once drug pressure is removed14. In some instances, 
loss of fitness may be associated with the development of compensatory mechanisms, leading to persistence of 
the mutant parasite in the population despite the discontinuation of the drug. This feature may explain, at least 
in part, the persistence of PfCRT-76 mutant37–39, even if CQ had not been used in these areas for many years. 
There are a series of additional factors that may be involved in the presence of phenotypic CQ resistance – such 
as PfMDR1 mutations40 – that were not assessed in this study and could lead to an underestimation of the real 
molecular resistance profile in the area. These factors could be the cause of remaining CQ resistance unrelated to 
the presence of PfCRT, and should be considered when monitoring molecular resistance in the future.
Overall, the encouraging results from this first exploratory trial and molecular analysis set the scene for subse-
quent studies to continue exploring the efficacy of CQ in clinical cases with higher parasitaemia, before any final 
recommendations are made with regards to the use of this drug in Mozambique. It could be argued that exposing 
children with clinical malaria to a drug that has only shown partial efficacy to clear infections in semi-immune 
adults with low-density, may be hard to justify based on the presented data. Indeed, this population, with alleg-
edly lower levels of acquired immunity to malaria due to their age, may be more vulnerable to the infection, and 
at higher risk of responding poorly to a partially effective drug. Thus, as a next step, we aim to continue testing 
the in vivo efficacy of CQ among adults, but this time enrolling only those with clinical symptomatology derived 
from their infections, and higher parasite densities on admission. Only if chloroquine shows good efficacy in this 
population, we will deem it possible to start evaluating CQ’s real life efficacy among infected sick children.
In the context of malaria elimination, CQ exhibits two conditions that make it attractive for elimination cam-
paigns: 1) It has been demonstrated to have an excellent safety profile, allowing for its use in all age groups includ-
ing pregnant women and young children; and 2) Its relatively long elimination half life (t1/2 = 1–2 months)41 
can provide a long post-treatment prophylactic effect. Thus, CQ could be a drug of choice in malaria elimination 
efforts such as in MDA campaigns, in combination with a highly effective anti-malarial. It could also be used in 
similar contexts for those populations who cannot receive ACTs, such as pregnant women in the first trimester, 
or very young children, as the safety of CQ in such populations has widely been demonstrated. Finally, through 
this innovative use of CQ, the drug pressure exerted to the circulating parasites would be minimal, and risk for 
re-introduction of resistant mutations would be very low.
Conclusion
This study shows that CQ could play a role, on its own or in combination with other drugs or tools, as part of 
malaria elimination efforts at the population level, both on account of its therapeutic efficacy but more impor-
tantly by means of its chemoprophylactic activity and safety profile.
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